We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Evgen Pharma Plc | LSE:EVG | London | Ordinary Share | GB00BSVYN304 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.80 | 0.75 | 0.85 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 422k | -4.04M | -0.0147 | -0.54 | 2.2M |
Date | Subject | Author | Discuss |
---|---|---|---|
04/2/2021 15:15 | Thats a bit of an over reaction for someone who constantly repeats himself. | kingalf | |
04/2/2021 15:13 | That's the wrong thread you pillock, your post is still on Advfn thicko...it's been removed from the LSE thread, no doubt because they've clocked your muliple avatars and snide agenda....ha ha ha ha...;-) | moneymunch | |
04/2/2021 14:54 | Small time lowlife spread betters, short on Evgen's placing news, except the share price has gone UP...ha ha ha ha .....Gla holders...more good news could drop at anytime.... ;-) | moneymunch | |
04/2/2021 14:40 | And just to say EVG is a trade for me in the short term not an investment. Until they sort out breast cancer, I can’t see a long term plan. | nobbygnome | |
04/2/2021 14:39 | On target, no doubt what they find particular irksome is that Evgen's share price sits in double figures and not the 8p they were expecting....ha ha ha ha.....Nobby's on record stating that SFX-01 will never be approved for Covid/ARDS.....and so let's hope he'll be squirming soon on the DSMB's assessment and Huw's update thereafter. Gl ;-) ps the Directors participation in the placing is totally irrelevant imho and illustrates the desperation from those that are trying to undermine proceedings. | moneymunch | |
04/2/2021 14:37 | I have been consistently negative on IMM. However that doesn’t stop me from buying short term for a significant event because I am not blinkered like most here. | nobbygnome | |
04/2/2021 14:36 | moneymunch, I have witnessed Nobbygnome blow hot and cold on other shares such as IMM. He talks his book I think - and like I said yesterday I wouldn't be surprised if he wants to increase his holding, perhaps at a lower price. | on target | |
04/2/2021 14:35 | Dear oh dear. Some of us have balanced views and don’t see everything through rose tinted glasses. I am on record as saying that the breast cancer indication is of most interest to me. However, the drug is hardly the panacea as it didn’t work in SAH and is unlikely to work in Covid 19. The current market cap will tell you the market agrees with me on the latter. Of course any indication that it does work such as passing the futility and safety interim analysis and the price will go up substantially. I am invested here with my eyes open and am not a blind disciple! | nobbygnome | |
04/2/2021 14:31 | Do you agree with kingalf that SFX-01 is just a scam then Nobbygnome? I do agree that the meagre £5k participation from Huw was discomforting, but it's not a reason not to hold imo. | on target | |
04/2/2021 14:30 | ps Nobby, why don't you let kingoaf know about the relationship that you were trying to build with one of the breast cancer patients. | moneymunch | |
04/2/2021 14:28 | Bloody hell, who would have thought...Nobby's on the same side as troll boy....not to be trusted imho...Gla ;-) | moneymunch | |
04/2/2021 14:24 | As predicted....a hissy fit ensued! | nobbygnome | |
04/2/2021 14:18 | >> kingcalf I think you are about to see a hissy fit from our resident ramper. However, there is some truth in what you say. The lack of meaningful participation in the fund raising by the directors is very concerning to me! | nobbygnome | |
04/2/2021 14:14 | Jeez are you for real....at long last showing your true colours and snide agenda...you claimed yesterday that you had just sold out....ha ha ha....you sad little troll...ho ho ho....and as far your ridiculous juvenile statement that SFX-01 and Sulforaphane is a scam based science , you tell that to the patients who were involved in the breast cancer trials, where SFX-01 proved life changing for some....you are unbelievable and an utter disgrace.....you really don't have a clue , now get back under your stone you sad pathetic low life troll creature....Gla holders....the green light from the DSMB will be transformational for all concerned and add significant value....coming soon!!!! :-) | moneymunch | |
04/2/2021 14:05 | You sound a bit like someone who sold out yesterday and was expecting the shareprice to go down? Wonder why that is? Do tell us the price you sold at so we can all have a good laugh in a few weeks time. | on target | |
04/2/2021 12:30 | Nobody here got the feeling that we have just been shafted by FinnCap ? | mesquida | |
04/2/2021 09:33 | VAL waking up ! | amaretto1 | |
04/2/2021 08:59 | Hi Bumpa, we know that they have plans for IND on the breast cancer programme, but could also be related to glioma target, given how excited Huw is on the pre-clinical data, and take your pick on the new cancer indication, presumably related to SHP2, and could include Noonan Syndrome, "a very rare developmental disorder in children", given the work already published by Prof Phil Eaton on the therapeutic benfits of SFX-01 on this disorder. Gl ;-) 16th July 2020 Current and planned work programme All preclinical breast data published in high impact journal in June 2020 Extensive review of clinical pathway to approval close to completion Supplementary preclinical work required to confirm CDK4/6i “resistance-br New “commercial ready” solid tablet formulation to be completed in H3 2020 Targeting CTA/IND in H1 2021 with first patient first dose in Q2/Q3 2021 | moneymunch | |
04/2/2021 08:42 | Surprised this hasn’t been discussed. | bumpa33 | |
04/2/2021 08:40 | the market for ‘longevity science’ will be enormous - it is the holy grail for the human race after all - so even a tiny slice of that would be a life changing investment. So mm, what d’ya reckon the “cancer indication yet to be announced” is...? | bumpa33 | |
04/2/2021 07:32 | Amazing prospects amarreto across multiple targets from a modest market cap, near term its all about SFX-01's Covid/ARDS patient trials....a positive assessment from the DSMB on the first 100 patients recruited will be massive news, and then multiple upside opportunies on the rest of the pipeline as good news rolls in, and then who knows what future opportunies Jim Mellon's £10.5m plus royalties licensing deal could provide, not just as a healthcare supplement as planned, but Evgen could devlop SFX-01 in the not too distant future as an anti-aging pharmaceutical now that there is strong evidence of Sulforaphane's anti-aging properties.....which undoubtedly will be big business and boomtime for those that succeed. Gl ;-) ................. The European startups hacking the ageing process The innovations that will extend our lives and delay the definite end. 25 January 2021 For the first time in human history, more people die from diseases that come as a consequence of old age — such as cancer and heart attacks — than infectious disease. It is also the first time in history that humans are just starting to understand what actually makes us age, with a whole new science emerging around concepts like telomere attrition, epigenetic alterations and zombie cells. Just a few months ago, scientists in Tel Aviv managed to actually reverse the ageing process for the first time ever. These forces have led to a whole new ecosystem of early-stage biotech companies and VC investors with a bold mission: curing ageing. While still dominated by the US, this is an emerging force in European biotech as well. We are living in the first iteration of humans on the planet that for the very first time understands, on a biochemical level, what makes us age. The UK-US company Juvenescence is creating a network for longevity companies, scientists as well as AI specialists. It has so far invested in approximately 15 startups. The hopes to IPO in the coming year. | moneymunch |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions